Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine

Leukemia. 2016 May;30(5):1190-4. doi: 10.1038/leu.2015.250. Epub 2015 Sep 15.

¹ Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
² Division of Hematology/Oncology, Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
³ USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
⁴ Cell Signaling Technology, Danvers, MA, USA.
⁵ Leukemia Program, Department of Hematology/Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

No abstract available

Publication types